PF-04937319 is identified by CAS 1245603-92-2, has the molecular formula C22H20N6O4, and the PF-04937319 molecular weight is 432.43 g/mol. Its partial profile was designed to retain glucose-lowering activity while limiting maximal enzyme activation.
Glucokinase links glucose availability to insulin secretion in pancreatic beta cells and glucose processing in hepatocytes. Activity in both tissues enables researchers to study the effects of systemic activation.
Application of PF-04937319
Nerigliatin is used to compare partial and full glucokinase activation in enzyme assays, islet cultures, hepatocyte models, and glucose-tolerance studies. These systems connect biochemical potency with insulin secretion, glucokinase translocation, and postprandial glucose responses.
As a clinical-stage benchmark, the compound also helps assess whether partial activation can support glycemic control while reducing, but not eliminating, hypoglycemia-related liabilities.
In Vitro
Biochemical testing of the PF-04937319 structure showed partial glucokinase activation with a reported EC50 of approximately 0.17 μM (170 nM). In islet cultures, it enhances glucose-stimulated insulin secretion. In hepatocytes, it promotes glucokinase translocation from the nucleus to the cytoplasm, making more enzyme available for glucose phosphorylation.
Together, these assays distinguish direct enzyme activation from downstream cellular responses. Glucose concentration and cellular context should be controlled because both can affect the measured response.
In Vivo
In rats, oral administration reduced postprandial plasma glucose during an oral glucose tolerance test. Randomized studies of Pfizer PF-04937319 in adults with type 2 diabetes inadequately controlled on metformin also demonstrated glucose lowering during the study periods. Clinical studies included active-comparator arms with sitagliptin or titrated glimepiride, depending on the study design.
The trials confirmed clinical pharmacodynamic activity but did not establish long-term durability. Because glucokinase activation can increase the risk of hypoglycemia, the partial-activation profile should not be considered risk-free.
Biochemical and Physiological Actions
Glucokinase phosphorylates glucose to glucose-6-phosphate. PF-04937319 binds an allosteric site and stabilizes a more active conformation, lowering the glucose concentration required for activation. Its partial profile limits the maximal shift relative to full activators.
In beta cells, increased glucose phosphorylation supports ATP production and glucose-dependent insulin secretion. In the liver, it favors glucose utilization and glycogen synthesis. These linked actions explain the glucose-lowering rationale and the need to assess responses at low glucose concentrations.
Features and Benefits of PF-04937319
- Defined PF-04937319 chemical structure containing benzofuran, pyrazine, and pyrimidine carboxamide features.
- PF-04937319 molecular weight of 432.43 g/mol for the formula C22H20N6O4.
- Partial glucokinase activation with reported nanomolar biochemical potency.
- Measurable responses in enzyme, islet, hepatocyte, animal, and clinical studies.
- Useful comparator for investigating efficacy and safety trade-offs within the glucokinase activator class.
Powered by Bioz